Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 1 (1)

Trial Status

Unknown1
Recruiting1
Enrolling By Invitation1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07089550RecruitingPrimary

PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)

NCT06835244Enrolling By InvitationPrimary

Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms

NCT04429451Phase 1UnknownPrimary

PSMA-specific CAR-T Cell Therapy

Showing all 3 trials

Research Network

Activity Timeline